Background: Upper tract urinary carcinoma (UTUC) is a relatively uncommon but aggressive disease. The Ki-67 antigen is a classic marker of cellular proliferation, but there is still controversy regarding the significance and importance of Ki-67 in tumor progression. Methods: In this study, we first detected Ki-67 expression in UTUC patients by immunohistochemistry (IHC). Subsequently, we quantitatively combined the results with those from the published literature in a meta-analysis after searching several databases. Results: IHC results demonstrated that patients with muscle-invasive tumors (T2-T4) had higher Ki-67 expression than those with non-muscle-invasive tumors (Tis-T1), suggesting that high Ki-67 expression may be associated with the aggressive form of UTUC. Kaplan-Meier curves showed that patients with high Ki-67 expression had significantly poorer cancer-specific survival (CSS) and disease-free survival (DFS). Furthermore, multivariate analysis suggested that Ki-67 expression was an independent prognostic factor for CSS (hazard ratio, HR=3.196) and DFS (HR=3.517) in UTUC patients. Then, a meta-analysis of the published literature investigating Ki-67 expression and its effects on UTUC prognosis was conducted. After searching the PubMed, Medline, Embase, Cochrane Library and Scopus databases, 12 articles met the eligibility criteria for this analysis. The B. Fan and H. Zhang contributed equally to this work.
Introduction
Upper tract urinary carcinoma (UTUC) is a relatively uncommon but aggressive disease that accounts for only 5-10% of all urothelial malignancies [1, 2] and has an estimated annual incidence in Western countries of approximately 2 cases per 100,000 inhabitants [3] . As previously reported, the ratio of urothelial carcinoma in the renal pelvis and ureter is reported to be 3:1 [4, 5] . Sixty percent of UTUCs are invasive at diagnosis compared with 15-25% of bladder tumors [6, 7] . UTUCs have a peak incidence in individuals aged 70-90 years and are three times more common in men [8, 9] . Although radical nephroureterectomy (RNU) with bladder cuff excision is the standard treatment for UTUC, the urothelial cancer often recurs in the bladder after surgery. However, 22-50% of patients undergoing RNU develop postoperative intravesical recurrence during the follow-up period [10] [11] [12] . When UTUC invades the muscle wall, the 5-year specific survival rate is less than 50% for pT2/pT3 cases and less than 10% for pT4 cases, indicating poor prognosis [13] [14] [15] [16] . A more accurate knowledge of the exact molecular mechanisms of tumor invasion and recurrence would improve UTUC prognostic accuracy and would benefit patients Cell proliferation is an important prognostic indicator of recurrence, aggressiveness and progression of tumors [17] . The Ki-67 antigen is a classic marker of cellular proliferation because it is preferentially expressed during the late G1, S, G2 and M phases of the cell cycle, whereas it is absent from resting cells in G0 phase; thus, it is an excellent marker for determining the growth fraction of a cell population [18] [19] [20] . Indeed, previous studies reported that Ki-67 expression was associated with tumor stage, grade, and recurrence in patient with bladder cancer [21] . However, there is still a debate regarding the significance and importance of Ki-67 in tumor progression because several studies identified it as a poor prognostic marker in UTUCs [22, 23] , while others disagreed with these reports [24, 25] . Since evidence for its current role in UTUC is relatively poor, and few studies on Ki-67 molecular mechanisms in UTUC performed in Chinese mainland patients are available, it is of utmost importance to combine these data to reach a reasonable conclusion.
Therefore, the present study is focused on the retrospective evaluation of Ki-67 expression and its association with conventional pathological parameters and prognosis of patients. For this purpose, a systematic review and meta-analysis of published literature investigating the role of Ki-67 expression and its effects on UTUC prognosis were performed to help define individualized and closer follow-ups for marker-positive patients.
Materials and Methods

Study population
The present research was sanctioned by the Institutional Research Ethics Committee of the First Affiliated Hospital of Dalian Medical University (No. LCKY2015-08), and informed consent was provided by all 94 patients who underwent RNU between January 2008 and December 2013; diagnosis with UTUC was affirmed by clinical resection and pathology. Patients who received neoadjuvant chemotherapy, who had distant metastatic lesions at surgery and with previous or concurrent urothelial carcinoma of the bladder were excluded from the present study. Surgery was performed by several surgeons according to the standard criteria for RNU.
Histopathological evaluation
All surgical specimens were processed using standard pathological procedures, and hematoxylin and eosin (H&E)-stained slides from all cases were reviewed by genitourinary pathologists without any knowledge of the clinical outcomes. Tumors were pathologically staged according to the 2002 TNM classification of the American Joint Committee on Cancer, and tumors were graded according to the 1998 WHO/International Society of Urologic Pathology consensus classification [26] .
Immunohistochemical staining
Formalin-fixed, paraffin-embedded tissues were cut into 4 μm thick sections and were then deparaffinized with xylene and rehydrated through a graded alcohol series. For antigen retrieval, the slides were placed in 10 mM citrate buffer (pH 6.0) and boiled for 20 min. Then, 3% hydrogen peroxide in methanol was used to block the endogenous peroxidase activity. The slides were incubated with the first antibody, rabbit polyclonal anti-Ki-67 (1:100, ProteinTech Group, Chicago, IL, USA), at room temperature for an hour and then with the second antibody. HRP-linked anti-rabbit/anti-mouse IgG antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1:1000). For immunohistochemical staining, an EliVision plus kit (Maixin-bio, Fuzhou, China) was used, diaminobenzidine (DAB) staining was performed and the slides were counterstained with hematoxylin. Images were captured with an Olympus BX51 microscope (Japan).
Immunohistochemical analysis
Immunostaining was evaluated and scored by two of the authors (Y.G and HL. W), who were blinded to the clinicopatholgical data. We obtained the immunohistochemistry results using 10 random hotspots in the tumor cells with each specimen at 200-fold magnification. Staining for Ki-67 was performed on the primary tumor as described previously [22] . The samples were classified into the following groups: low Ki-67 expression (≤20% of cell nuclei stained positive for Ki-67) and high Ki-67 expression (>20%).
Statistical analysis SPSS 20.0 statistical software (SPSS Inc., Chicago, USA) was used to assess Ki-67 prognostic significance. Pearson's χ 2 test and Spearman's correlation analysis were applied to investigate the association between Ki-67 expression and patient characteristics. The Kaplan-Meier method was used to compare the diseasefree survival (DFS) and cancer-specific survival (CSS) between the groups using the log-rank test. DFS was considered the interval between the date of UTUC surgery and the time of appearance of the first locoregional recurrence or distant metastasis. CSS was defined as the interval between the date of UTUC surgery and the time of UTUC-related death [27] . The potential prognostic factors were established by univariate analysis, and only the significant factors were entered into multivariate Cox proportional hazard regression models. Differences were considered statistically significant when the p value was less than 0.05.
Meta-analysis
Search Strategy. We searched the PubMed, Medline, Embase, Cochrane Library and Scopus databases to identify relevant studies evaluating the immunohistochemical expression of Ki-67 and its effects on UTUC prognosis from inception until April 2015. The following words and medical subject headings that included all spellings were used: "Ki-67", "Immunohistochemistry", "Upper urinary tract", "Renal pelvis", "Ureter", "Urothelial cancer", "Urothelial carcinoma", and "Prognosis". To obtain all-sided data of relevant articles, further eligible bibliographies were hand-searched, and company reports were sought. No restrictions for language or time of publication were applied.
Selection Criteria. Studies satisfying the following criteria were included in our analysis: (1) the histologic type of the tumors was urothelial carcinoma; (2) Ki-67 protein expression was evaluated in the upper urinary tract tissue; (3) Ki-67 expression was evaluated in tissues by IHC; (4) the association between Ki-67 expression levels and survival outcome was investigated. Accordingly, the following exclusion criteria were applied: (1) studies in form of reviews, letters to the editor, commentaries, or case reports that lacked original data; (2) laboratory studies, such as studies on cancer cell lines and animal models; (3) studies that did not provide information on survival; (4) studies in which the hazard ratio (HR) and its standard error could not be calculated based on the given information. Data extraction. To decrease the risk of losing a publication, a rigorous process was independently carried out by two investigators (Bo Fan and Hongshuo Zhang), who considered potentially relevant studies based on the predefined criteria. A third reviewer (Xishang Song) assessed the resulting extractions and resolved any discrepancies between the independent search results. Data retrieved from the reports included author, year of publication, region, study type, recruitment period, number of patients, demographics (age, sex), pathologic grade, cut-off value, HR, and 95% confidence interval (CI) of reported endpoints, including disease-free survival (DFS), cancer-specific survival (CSS), overall survival (OS), metastasis-free survival (MFS) and recurrence-free survival (RFS). The definition of DFS and CSS has been introduced previously; OS was defined as the interval between the date of UTUC surgery and the time of death. MFS and RFS were considered the interval between the date of UTUC surgery and the time of appearance of distant metastasis or the first locoregional recurrence, respectively.
Statistical analysis. We estimated the HR with 95% confidence interval (CI) for dichotomous outcomes. Heterogeneity of the included studies was evaluated using the χ 2 test, a qualitative analysis to evaluate statistical heterogeneity, and the I 2 test, a quantitative analysis measuring the percentage of inconsistency. If the heterogeneity p-value was > 0.1 in the χ 2 test, indicating no heterogeneity among studies, fixed-effects models were applied to estimate the pooled HR of each study. Otherwise, the random effects models were used. The I 2 -value in the I 2 test delineated the proportion of total variation that is due to heterogeneity rather than errors of sampling, and an I 2 > 50% indicates high heterogeneity. The potential for bias was assessed by inspection of a funnel plot and Egger's test if the number of studies included in each analysis was ≥10. Otherwise, publication bias was not tested because of the limited number (below 10). The results were considered statistically significant at two-sided p-values <0.05. All statistical analyses were performed using Stata 12.0 (Stata Corporation, College Station, TX, USA).
Results
Association of Ki-67 expressions with the clinicopathological characteristics of UTUC
To investigate the clinical relevance of Ki-67 expression in high-grade UTUC, the levels of Ki-67 in the patients' tumor lesions were determined by immunohistochemistry (IHC) (Fig. 1A-D) . Based on the staining intensity, we subdivided 94 UTUCs patients into two groups: the "low Ki-67" UTUC group included 62 tissue samples characterized by weak and low Ki-67 staining (≤20% of cell nuclei stained positive for Ki-67), while the "high Ki-67" 
The impact of Ki-67 expression on CSS in UTUC
To determine whether Ki-67 expression level is a significant predictor for CSS after radical nephroureterectomy, Kaplan-Meier curves were analyzed between high or low Ki-67 and CSS. The CSS of patients with high Ki-67 expression was significantly lower than those with low Ki-67 (p=0.017; Fig. 2A ). Univariate analysis showed that lymph node metastases and high Ki-67 expression were related to a poor overall survival for patients with UTUCs. Multivariate analysis showed that high Ki-67 expression (HR=3.196; 95% CI=1.013-10.086; p=0.048) and lymph node metastases (HR=3.469; 95% CI=1.031-11.670; p=0.045) were independent prognostic factors for CSS. The results are shown in Table 2 .
The impact of Ki-67 expression on DFS in UTUC
Kaplan-Meier analysis demonstrated that high Ki-67 expression was significantly associated with poor DFS (p=0.020) (Fig.  2B ). In addition, the DFS was significantly shorter in the Ki-67 high expression group compared with the Ki-67 low expression group (p=0.037; Fig. 2) . Furthermore, these associations were confirmed by Cox univariate analysis (HR=3.517; 95% CI=1.006-12.299; p=0.049) and multivariate analysis, with adjustments for lymph node status (HR=3.207; 95% CI=0.999-10.299; p=0.050) ( Table 3) .
Identification and eligibility of relevant studies in the meta-analysis
A detailed flowchart of the search and selection results is shown in Fig. 3 . The initial Fig. 2 . Kaplan-Meier curves for cancer specific survival (A) and disease-free survival (B) according to Ki-67 expression in patients with upper tract urothelial carcinoma (UTUC). Patients with high Ki-67 expression exhibited a significantly worse cancer-specific survival (CSS) rate and disease-free survival (DFS) rate than patients with low Ki-67 expression (p=0.017, 0.037, respectively, log rank test).
The major characteristics of the thirteen included cohort studies are shown in Table 4 . These studies were published between 1996 and 2014. In total, five were conducted in Japan [23, 24, 32] , three in China [25, 35] , two in Korea [22, 31] , one in the USA [30] , one in Spain [29] , and one in a multi-institutional study [28] . The sample size of the studies ranged from 37 to 475 (a total of 546). Three studies enrolled patients with high grade UTUCs [28, 30] , and the remaining 12 studies included patients with all grades of UTUCs [22-25, 29, 31-35] . The cut-off value used to define Ki-67 overexpression was less than or equal to 20% in ten studies [22-25, 28-31, 34] , whereas in the remaining 3 studies [32, 33] , the cut-off value was 24% or 30%.
Meta-analysis of Ki-67 expression and UTUC patient survival
Among twelve eligible studies, which included a total of 767 patients with survival data, nine studies reported the relation between Ki-67 expression and cancer-specific survival (CSS) in UTUC, and the remaining analyses investigated overall survival (OS). Fig. 4A shows the forest plot for the survival data. The combined HR was 2.081 (95% CI=1.550-2.793, p＜0.001), indicating that increased Ki-67 levels were significantly associated with adverse survival in the pooled patient group. This result was not affected by study heterogeneity (I 2 =18.3%, p=0.264) and exhibited a low probability of publication bias, as determined by Egger's test (p=0.046, Fig. 4B ). In subgroup analysis, increased Ki-67 levels were associated with CSS with a pooled HR estimate of 2.276 (95% CI= 1.702-3.045, p＜0.001). However, a non-significant decreased risk of OS was observed in UTUC with high expression of Ki-67 (p=0.200).
Meta-analysis of Ki-67 expression and UTUC disease progression
According to the definition of related endpoints in several studies, including ours, recurrence-free survival (RFS), metastasis-free survival (MFS) and disease-free survival (DFS) are indicators of disease progression, such as locoregional recurrence or distant metastasis. Thus, we combined these overlapping endpoints for a higher power of analyses, as the included studies examining RFS, MFS and DFS were few. Forest plots of the metaanalyses for Ki-67 expression are depicted in Fig. 5A . Combined data from eight studies showed that increased Ki-67 levels were related to disease progression, with a pooled HR estimate of 2.791 (95% CI=1.611-4.835, p＜0.001) and a moderate degree of heterogeneity (I MFS and DFS, with a pooled HR estimate of 3.008 (95% CI=1.460-6.197, p=0.003) and 6.336 (95% CI=1.558-25.772, p=0.010), respectively. However, the combined HR was 1.954 (95% CI=0.826-4.621, p=0.127), indicating no significant overall association between Ki-67 expression and RFS. Begg's funnel plot did not show the asymmetry typical of publication bias, and the p value for Egger's regression asymmetry test was 0.125, indicating no publication bias (Fig. 5B) .
Discussion
The Ki-67 antigen, first described in 1983, is a labile, non-histone nuclear protein that is expressed in all phases of proliferating cells, except G0 and early G1 [36, 37] . This protein is encoded by the 15 exon-spanning MKI67 gene mapping to chromosome 10q26.2 [38, 39] . Moreover, Ki-67 expression is strongly associated with the percentage of growth, and this index is used for measuring tumor cell proliferation [40, 41] . Previous studies revealed that Ki-67 overexpression was an important event in patients with certain types 
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of cancer. Warth A analyzed the Ki-67 proliferation index in 1065 patients with non-small cell lung cancer (NSCLC) by IHC and found that the proliferation index is not only a clinically meaningful biomarker in NSCLC prognosis but may also potentially stratify patients with lung adenocarcinomas based on the need for adjuvant therapy [40] . In a meta-analysis evaluating the impact of Ki-67 on prognosis in patients with early breast cancer, Azambuja E showed that Ki-67 positivity was associated with a higher risk of relapse in both nodenegative patients (HR=2.31,95% CI:1.83-2.92) and node-positive patients (HR=1.59, 95% CI: 1.35-1.87) [42] . Furthermore, Klatte et al. reported that Ki-67 could serve as an independent predictor of DFS in localized chromophobe renal cell carcinoma [43] .
Our first results showed that 38% of the tumors from the patients enrolled in the current study expressed Ki-67 protein, although other researchers found frequencies ranging from 53-88%. However, these studies used different Ki-67 antibodies, sample sizes, cut-off staining values and elements that could have a role in the different results observed [22, 31, 35] . Moreover, we evaluated the association between Ki-67 expression and the clinicopathological features of patients with UTUC. Our results showed higher Ki-67 expression in patients with a muscle-invasive form of the tumor (T2-T4) compared with patients with the non-invasive form (Tis-T1), suggesting that the expression of this protein may be related to tumor aggressiveness. Krabbe et al. [28] reported Ki-67 expression in 14.9% of pT1 tumors and 60.8% of muscle-invasive tumors when the whole section was stained and taken into consideration, as well as a 20% expression threshold, results that are similar to ours. Thus, the detection and percentage of Ki-67 expression may be helpful for defining UTUC biological properties and may indirectly suggest the prognosis of patients. Above all, Ki-67 expression in UTUC patients' tissues detected by IHC was significantly correlated with CSS and DFS as determined by multivariate analysis, suggesting a role as an independent prognostic factor, which was also reported by another study [32] .
However, among the studies related to Ki-67 expression and its prognostic value in UTUC, different results were found. Feng C and their colleagues found a negative association between high Ki-67 expression and tumor prognosis and intravesical recurrence [25] . In another study, Hayashi et al. [24] reported that high Ki-67 expression was not an independent predictor of CSS or MFS in 171 UTUC patients who underwent RNU. Why are the results on prognostic significance of Ki-67 in UTUC patients different or conflicting? First, different experimental conditions may lead to these differences, such as region-specific, race-specific, sex-specific or age-specific factors. Second, the varying threshold values of Ki-67, different technical platforms and varying concentrations of the antibody used may influence IHC results and produce statistical heterogeneity [44] [45] [46] . Finally, in breast cancer, the Ki-67 effect is in opposite directions for assessment of prognosis and for assessment of neoadjuvant response. Denkert et al. suggested that the biological explanation for these results is that there are different groups of tumors in breast cancer. When highly proliferating tumors are sensitive to chemotherapy, high Ki-67 may be related to an increased chance of pathological complete response and improved survival, suggesting that high Ki-67 is linked to good outcomes; however, when highly proliferating tumors are chemotherapy resistant, increased Ki-67 indicated poor outcome or reduced survival in breast cancer patients [47, 48] . Thus, Ki-67 may be both a prognostic and a predictive marker.
Since meta-analysis can combine studies on specific topics and RNU is less influenced by individual findings from a single study, we performed a systematic review of published articles related to the changes in Ki-67 and their effects on UTUC prognosis. Hence, our present report combined 12 independent studies, selected according to the enrollment criteria, which compared UTUC survival with Ki-67 expression in the primary tumor. The data were organized according to the assessment of patient survival (cancer-specific and overall survival) and disease progression (metastasis-free, recurrence-free and disease-free survival). Our results further clarify and elucidate the strong association between Ki-67 overexpression and progression, metastasis and mortality in UTUC.
Our cohort study has several limitations. First of all, it is a retrospective study of samples from patients with a relatively uncommon disease enrolled from only one university hospital.
In addition, we could not standardize the surgical procedure because different surgeons were involved and different surgical approaches were used. Furthermore, since the sample size was not large compared with previously reported multicenter studies, the analysis of several potential risk factors, such as pathological stage, lymph node status, and tumor focality, showed limited statistical power. Moreover, since UTUC is characterized by unique biological features as well as heterogeneous genetic backgrounds, it may be difficult to apply specific conventional parameters alone to predict postoperative outcomes in patients with UTUC [49] [50] [51] . Finally, some basic issues related to bias due to the exclusion of patients with distant metastatic lesions at surgery, those receiving neoadjuvant chemotherapy, and those undergoing systematic chemotherapy could affect our results. However, the clinical effects of such advanced cases are not based on bladder recurrence but rather on prognosis.
The meta-analysis results should be considered in the context of their strengths and limitations. The advantage of a meta-analysis is to provide a more precise estimation through the combination of the power of multiple studies with a large number of patients. Although we did not limit our literature search to only English language papers and extended the search to unpublished trials and abstracts that would likely include increased proportions of null results, potential bias cannot be completely avoided. Indeed, publication bias could arise as a result of selective 'positive' studies. In addition, the resulting HRs from multivariate survival analysis reported in the selected articles were included. When these results were not available, we extracted the univariate data [44] . When the individual HR together with its variance were not reported in the selected articles, we performed, when possible, a calculation from the survival comparison statistics and its variance. The estimated HR may be less reliable than the one obtained directly from published statistics [52] . Finally, when defining Ki-67 overexpression, the cut-off values for IHC varied from 6% to 30% among these studies [23, 29, 31, 35] . Indeed, there is no common threshold value to define Ki-67 positive expression in patients with UTUC. Therefore, standardized protocols will improve the quality of this study in the future.
Conclusion
Our retrospective cohort study and meta-analysis showed that Ki-67 overexpression may be a prognostic factor for patients with UTUC, although these findings need to be interpreted with caution. Ki-67 determination may help identify patients with UTUC at high risk of disease progression and poor prognosis, who might benefit from closer follow-up or more aggressive therapy. The value of Ki-67 for molecular staging of UTUC also needs to be further confirmed in adequately designed prospective trials involving larger number of patients before any definitive conclusions can be made.
